Entest Biomedical, Inc.
San Diego
California
United States
72 articles about Entest Biomedical, Inc.
-
Entest Biomedical, Inc. Announces 3 Million Share Zander Therapeutics, Inc. Dividend To Be Paid To Shareholders
9/29/2017
-
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc., Reports Its Series A Compounds Suppressed The Production Of Multiple Cytokines Known To Be Involved In Inflammation With No Toxicity In Canine Studies
6/14/2017
-
Entest Biomedical, Inc.'s Subsidiary EnteroMedics Reports On Preliminary Canine Experiments Testing New Anti-Inflammatory Drug Compounds
6/7/2017
-
Entest Biomedical, Inc. Settles $841,531 Of Principal Indebtedness Through The Issuance Of Equity Securities
5/31/2017
-
Entest Biomedical, Inc. Subsidiary Zander Therapeutics, Inc. Discusses Developments In Medicinal Chemistry For Veterinary Applications Of Cancer And Autoimmune Therapies Through Modulation Of Checkpoint NR2F6
5/24/2017
-
Entest Biomedical, Inc.'s Chairman Discusses Its Subsidiary, Zander Therapeutics, Inc.'s Progress With Small Molecule Immunotherapies For Treating Cancer And Arthritis In Dogs
4/27/2017
-
Entest Biomedical, Inc.'s Subsidiary, Zander Therapeutics, Inc., Initiates Ex Vivo Studies On Modulating NR2F6 In Canines
4/19/2017
-
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics, Inc. Announces Appointment Of Dr. Thomas Donnelly To Serve As Senior Veterinary Advisor
3/9/2017
-
Entest Biomedical, Inc.'s Zander Therapeutics, Inc. Unit Announces Publication Of Canine Cellular Immunotherapy Patent Application For Treating Cancer In Dogs
2/15/2017
-
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics Makes Key Additions To Management Team As The Company Prepares To Move Forward In The $63 Billion Veterinary / Pet Market Niche
2/6/2017
-
Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017
12/27/2016
-
Entest Biomedical, Inc.'s Zander Therapeutics Unit Files Composition Of Matter Patent On NR2F6 Modulating Small Molecules In Canine And Feline Applications
10/20/2016
-
Entest Biomedical, Inc.'s Zander Therapeutics Unit Files Patent Application On Ex Vivo Activated Autologous Immune Cells
8/11/2015
-
Entest Biomedical, Inc.'s Zander Therapeutics Unit: Initial Focus Is Small Molecule And Cancer Stem Targeting For Veterinary Oncology
8/4/2015
-
Entest Biomedical, Inc. In Discussions To Acquire Nanotechnology Delivery System For Cancer Therapy
6/2/2015
-
Entest Biomedical, Inc. Recruits Salk Institute for Biological Studies Researcher To Lead Cancer Stem Cell Program For Treating Feline Leukemia And Canine Cancer
7/16/2014
-
Entest Biomedical, Inc.'s ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous Side Effects
9/6/2012
-
Entest Biomedical, Inc. Sees Entry into $300 Million Veterinary Cancer Care Market Through Veterinary Hospital Acquisitions
9/4/2012
-
Entest Biomedical, Inc. Excited With Progress on 10 Dog Pilot Study of "Universal Donor" Stem Cell Treatment for Canine Osteoarthritis
3/21/2012
-
Entest Biomedical, Inc. Declares Dividend of Preferred Stock
2/13/2012